Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated enterovirus 71 vaccine (Jiangsu Provincial Center for Disease Control and Prevention)
- Development stage
- Unknown
- Lead developer
- Wuhan Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The inactivated EV-A71 vaccine is a Vero cell-derived, inactivated whole-virus vaccine designed to prevent hand, foot, and mouth disease (HFMD) caused by Enterovirus A71 (EV-A71). Developed through a collaboration between the Jiangsu Province Centers for Disease Control and Prevention and Beijing Vigoo Biological Co., LTD, the vaccine was licensed in China in December 2015. It is indicated for children aged 6 to 59 months and is typically administered as a two-dose series one month apart. Clinical trials have demonstrated high vaccine effectiveness, exceeding 90% against EV-A71-associated HFMD and severe disease. The vaccine works by inducing protective neutralizing antibodies against the EV-A71 pathogen, which is a major cause of neurological complications and mortality in pediatric HFMD cases.
- Other names
- inactivated EV-A71 vaccineInactivated Vaccine (Vero Cell) Against EV71EV-A71 vaccineEV-A-71 vaccineEV-A 71 vaccine
02
Targets
Enterovirus A71 capsid proteinHuman T-cell receptor specific for Enterovirus A71 peptide–MHC complexHuman B-cell antigen receptor specific for Enterovirus A71 epitopes
Beyond the preview
Go deeper on inactivated enterovirus 71 vaccine (Jiangsu Provincial Center for Disease Control and Prevention).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated enterovirus 71 vaccine (Jiangsu Provincial Center for Disease Control and Prevention).